



somalogic

Transforming research and revolutionizing healthcare

through precision medicine with
industry-leading, AI-data driven
proteomic technology

Our Mission

SomaLogic is fostering the discovery of new, effective and safer treatments for patients while empowering more accurate diagnosis, prevention and treatment of disease through the next generation of proteomics.

SomaLogic Advances the Power of Proteomics

SomaLogic uses protein data to improve human health and healthcare. The dynamics of proteomics translates into:



For Life Sciences:

Transformational research that discovers life-changing drugs and brings safer and more effective treatments to patients faster.



For Healthcare:

Revolutionizes the continuum of care from improving the accuracy of prognostic and diagnostic testing to uncovering new treatment options for patients through advances in precision medicine.

SomaLogic's pioneering platform provides more coverage of the proteome than any other technology.

SomaLogic currently measures **approximately 7,000 proteins**, more than twice as many as other proteomic technology platforms, and we are quickly moving toward 10,000 proteins. That's half of the approximately 20,000 proteins in your body.

Volume of content is a significant advantage in biomarker discovery.

The more proteins you measure, the more you are likely to find drug targets, new disease markers, new biology and unexpected effects.

Our proprietary SomaScan® Assay is the only technology that can measure:



BROADLY

approximately **7,000** proteins simultaneously



DEEPLY

high- and low-abundance proteins



RAPIDLY

high throughput in a small biological sample volume.

We use sophisticated machine learning and bioinformatics capabilities to transform this massive collection of data into quantitative risk assessments and reliable insights across many different human diseases and conditions.

Academic and biopharmaceutical researchers use our technology to accelerate biomarker discovery, diagnostics development, drug discovery and development, and health management.

SomaLogic Aptamers Deliver High Specificity with Superior Insights

SomaLogic's aptamer-based SOMAmer® reagents are just as specific as monoclonal antibodies and are — in fact — superior for doing discovery work because a greater number of data points (in this case the number of proteins measured) is more likely to result in novel insights and potential targets for drug discovery. Unlike polyclonal antibodies, SOMAmer reagents

are chemically synthesized, which means they are exactly the same from lot to lot, so protein binding is highly reproducible. The specificity of SOMAmer reagents and the robustness of the SomaScan® Assay have been demonstrated in over 400 peer-reviewed publications from users of our technology.

OUR PARTNERS

SomaLogic is unique because we're both a **life science tools company** and a **clinical diagnostics company**. We partner with leading life science and healthcare organizations.

For Life Sciences:

- SomaLogic has worked with **8 out of the 10 largest pharmaceutical companies** pursuing early drug research and development.
- **deCODE genetics, a subsidiary of Amgen** – In the [largest proteomic study to date](#), an Icelandic research team used SomaLogic's SomaScan® Platform to make the connection between genes and proteins and their impact on human diseases that span a variety of medical specialties and organ systems.

For Healthcare:

- **SomaLogic's SomaSignal™ Proteomics for Precision Medicine Initiative** – SomaLogic created the first large-scale, clinically focused partnership effort aimed at equipping healthcare providers with the power of proteomic technology to inform decisions at the point of care. We have partnered with:



SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.

NOTABLE FACTS

- September 2021 – Closed SPAC merger with CM Life Sciences II, Inc., began public trading on the Nasdaq Global Market under ticker "SLGC"
- Roy Smythe, M.D., Chief Executive Officer
- Larry Gold, Ph.D., Founder
- > 800 issued and pending patents
- > 400 scientific publications from [SomaLogic and third-party users](#)
- Built assay from 1,300 to approximately 7,000 proteins, more than twice as many as other proteomic technology platforms
- Quickly moving toward 10,000 proteins